Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Active:	Yes
Cancer Type:	Leukemia	NCT ID:	NCT04789655
Trial Phases:	Phase I	Protocol IDs:	CC-96191-AML-001 (primary) NCI-2021-02783 U1111-1264-5412
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Celgene
NCI Full Details:	http://clinicaltrials.gov/show/NCT04789655

Summary

This Phase 1, clinical study of CC-96191 will explore the safety, tolerability and
preliminary biological and clinical activity of CC-96191 as a single-agent in the setting of
Relapsed or refractory acute myeloid leukemia (R/R AML).

The dose escalation (Part A) of the study will explore escalating intravenous doses of
CC-96191 to estimate the MTD and/or RP2D of CC-96191 as monotherapy.

The expansion (Part B), will further evaluate the safety and efficacy of CC-96191
administered at or below the MTD in one or more expansion cohorts in order to determine the
RP2D.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.